Published in Cancer Weekly, July 26th, 2005
The shares were sold pursuant to the company's shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission. The company issued no warrants nor paid any commissions in conjunction with the transaction.
"This financing significantly strengthens the financial position of the company," said Steven W. King, Peregrine Pharmaceutical's president and CEO. "This funding will be utilized to advance our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.